Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G, Geschwind D, Vogel Z.

Br J Pharmacol. 2012 Apr;165(8):2512-28. doi: 10.1111/j.1476-5381.2011.01461.x.

2.

Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells.

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Gao F, Coppola G, Geschwind D, Vogel Z.

PLoS One. 2013 Apr 24;8(4):e61462. doi: 10.1371/journal.pone.0061462. Print 2013.

3.

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z.

J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12.

4.

Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells.

Juknat A, Rimmerman N, Levy R, Vogel Z, Kozela E.

Neurochem Int. 2012 Nov;61(6):923-30. doi: 10.1016/j.neuint.2011.12.002. Epub 2011 Dec 9.

PMID:
22178458
5.

Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells.

Juknat A, Kozela E, Kaushansky N, Mechoulam R, Vogel Z.

J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):289-96. doi: 10.1515/jbcpp-2015-0071.

6.

Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1.

Rimmerman N, Bradshaw HB, Kozela E, Levy R, Juknat A, Vogel Z.

Br J Pharmacol. 2012 Apr;165(8):2436-49. doi: 10.1111/j.1476-5381.2011.01380.x.

7.

The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells.

Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw HB, Vogel Z.

Cell Mol Neurobiol. 2011 Aug;31(6):921-30. doi: 10.1007/s10571-011-9692-3. Epub 2011 Apr 30.

PMID:
21533611
8.
9.

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V.

Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x.

10.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.

Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

PMID:
19785914
11.
12.

Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol.

Wright MJ Jr, Vandewater SA, Taffe MA.

Br J Pharmacol. 2013 Dec;170(7):1365-73. doi: 10.1111/bph.12199.

13.

Δ9-Tetrahydrocannabinol (Δ9-THC) attenuates mouse sperm motility and male fecundity.

Morgan DJ, Muller CH, Murataeva NA, Davis BJ, Mackie K.

Br J Pharmacol. 2012 Apr;165(8):2575-83. doi: 10.1111/j.1476-5381.2011.01506.x.

14.

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.

Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z.

J Neuroinflammation. 2016 Jun 3;13(1):136. doi: 10.1186/s12974-016-0603-x.

15.

Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.

Todd SM, Arnold JC.

Br J Pharmacol. 2016 Jan;173(1):53-65. doi: 10.1111/bph.13333. Epub 2015 Nov 18.

16.

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):191-8. doi: 10.1016/j.drugalcdep.2007.11.017.

17.

Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.

Carrier EJ, Auchampach JA, Hillard CJ.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7895-900. Epub 2006 May 3.

18.

Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.

McHugh D, Page J, Dunn E, Bradshaw HB.

Br J Pharmacol. 2012 Apr;165(8):2414-24. doi: 10.1111/j.1476-5381.2011.01497.x.

19.

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.

Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z.

Br J Pharmacol. 2011 Aug;163(7):1507-19. doi: 10.1111/j.1476-5381.2011.01379.x.

20.

The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model.

Scott KA, Dalgleish AG, Liu WM.

Mol Cancer Ther. 2014 Dec;13(12):2955-67. doi: 10.1158/1535-7163.MCT-14-0402. Epub 2014 Nov 14.

Supplemental Content

Support Center